Scalper1 News
Biotech Amgen (AMGN) reported Monday that a late-stage trial of its cholesterol drug evolocumab met its primary endpoint, sending Amgen stock up 2% in morning trading on the stock market today. The trial tested the potency of evolocumab in lower LDL (or “bad”) cholesterol in patients with homozygous familial Scalper1 News
Scalper1 News